The titer of anti-MDA5 Abs was influenced by the treatment for ILD complicated with dermatomyositis [29] and the results of anti-MDA5 Ab levels in this study would be modified by the treatment for RA or RA disease activities. This evidence concerns the gene IFIH1 and dermatomyositis.